Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMCnyeso
- Development stage
- Phase 1
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMCnyeso is a bispecific immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) molecule developed to treat advanced cancers by redirecting the body's own immune system. It consists of a soluble affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A*02:01 (HLA-A*02:01)-restricted cancer-testis antigens NY‑ESO‑1 and LAGE‑1A fused to an anti-CD3 single-chain variable fragment. This design enables the drug to target tumor cells expressing these antigens and recruit cytotoxic T cells for targeted killing. IMCnyeso was primarily investigated in patients with advanced solid tumors such as non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma (bladder cancer), and synovial sarcoma who are HLA-A*02:01 positive with tumors expressing NY‑ESO‑1 or LAGE‑1A[2][5][6]. The drug was administered as weekly intravenous infusions in clinical trials but development has been discontinued[2][6].
- Other names
- NY-ESO-1 ImmTACNY-ESO1 ImmTACNY-ESO 1 ImmTACNY-ESO-ImmTACbispecific NY-ESO-1 and LAGE-1A-specific TCR/anti-CD3HLA-A*0201-restricted NY-ESO-1 and LAGE-1A-specific soluble TCR/anti-CD3 bispecific molecule
02
Targets
CD3 (T-cell surface glycoprotein CD3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on IMCnyeso.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMCnyeso.